Evidence map›Paper›PMID 34222274›Full record

ReviewFrontiers in medicine2021

Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in Brazil.

Tais Hitomi Wakamatsu, Myrna Serapião Dos Santos, Telma Pereira Barreiro, Ana Estela Besteti Pires Ponce Sant'Anna, Fabíola Murta, Alexandre Xavier da Costa, Leonardo Guedes C Marculino, Rafael Jorge Alves de Alcântara, Charles Costa de Farias, José Álvaro Pereira Gomes

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frontiers in pharmacology · 2024
    Article
  2. Impact of Exposomes on Ocular Surface Diseases.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tais Hitomi WakamatsuDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Myrna Serapião Dos SantosDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Telma Pereira BarreiroDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Ana Estela Besteti Pires Ponce Sant'AnnaDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Fabíola MurtaDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Alexandre Xavier da CostaDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Leonardo Guedes C MarculinoDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Rafael Jorge Alves de AlcântaraDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Charles Costa de FariasDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
José Álvaro Pereira GomesDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute and potentially fatal inflammatory vesiculobullous reactions that affect the skin and mucous membranes, and which are most often triggered by particular medications and infections. In Brazil, the drugs most frequently associated with TEN and SJS include cold medicine such as dipyrone and NSAIDs, followed by carbamazepine, phenobarbital, penicillin, and allopurinol. Genetic variations have been found to increase the risk of SJS/TEN in response to triggering factors such as medications. The most closely associated genes found in Brazilian cold-medicine-related SJS/TEN patients with severe ocular complications are HLA-A

Indexed as

Brazilclinical aspectsgenetic predispositionStevens-Johnson syndrometoxic epidermal necrolysistreatment

Identifiers

PMID34222274
PMCPMC8252916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.